Home » Stocks » CSII

Cardiovascular Systems, Inc. (CSII)

Stock Price: $41.38 USD -0.52 (-1.24%)
Updated Mar 2, 2021 4:00 PM EST - Market closed
Market Cap 1.66B
Revenue (ttm) 228.43M
Net Income (ttm) -20.19M
Shares Out 38.81M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $41.38
Previous Close $41.90
Change ($) -0.52
Change (%) -1.24%
Day's Open 41.72
Day's Range 40.95 - 42.09
Day's Volume 131,731
52-Week Range 26.00 - 48.28

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 weeks ago

ST. PAUL, Minn.--(BUSINESS WIRE)--CSII Q3 Conferences

Zacks Investment Research - 3 weeks ago

Cardiovascular System's (CSII) Diamondback 360 Coronary OAS provides physicians in Europe with an effective treatment option for difficult-to-treat patient population.

Business Wire - 3 weeks ago

ST. PAUL, Minn.--(BUSINESS WIRE)--First patient treated in Europe

Zacks Investment Research - 3 weeks ago

Cardiovascular Systems (CSII) registers dismal revenues despite gradual recovery in business amid the pandemic.

Zacks Investment Research - 3 weeks ago

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 100.00% and -1.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead fo...

Benzinga - 3 weeks ago

Shares of Cardiovascular Systems (NASDAQ:CSII) were unchanged in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 100.00% year over ye...

Business Wire - 3 weeks ago

ST. PAUL, Minn.--(BUSINESS WIRE)--CSI Q2 Financial Results

Business Wire - 3 weeks ago

ST. PAUL, Minn.--(BUSINESS WIRE)--CSI Q2 Financial Results

Business Wire - 1 month ago

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES PARTNERSHIP WITH CHANSU VASCULAR TECHOLOGIES, LLC TO DEVELOP NEW DRUG-COATED BALLOON TECHNOLOGY

Business Wire - 1 month ago

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES SACHIN H. JAIN, MD, MBA, JOINS BOARD OF DIRECTORS

Zacks Investment Research - 1 month ago

Cardiovascular Systems (CSII) aims to expand treatment options in Europe for patients suffering from severely calcified coronary artery disease following the receipt of regulatory clearance.

Business Wire - 1 month ago

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. RECEIVES CE MARK FOR DIAMONDBACK 360® CORONARY ORBITAL ATHERECTOMY SYSTEM

Business Wire - 1 month ago

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO WEBCAST FISCAL 2021 SECOND-QUARTER EARNINGS CONFERENCE CALL WEDNESDAY, FEBRUARY 3

Business Wire - 1 month ago

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PRESENT AT THE 23RD ANNUAL NEEDHAM VIRTUAL GROWTH CONFERENCE

Zacks Investment Research - 2 months ago

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?

Business Wire - 3 months ago

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PRESENT AT THE STIFEL 2020 VIRTUAL HEALTHCARE CONFERENCE

Zacks Investment Research - 3 months ago

Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.

Seeking Alpha - 3 months ago

Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q1 2021 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 78.26% and 7.59%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for...

Business Wire - 3 months ago

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2021 FIRST-QUARTER FINANCIAL RESULTS

Zacks Investment Research - 4 months ago

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2021 first-quarter conference call on Wednesday, November 4, 2020, a...

Business Wire - 4 months ago

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for pa...

Business Wire - 4 months ago

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for pa...

Zacks Investment Research - 5 months ago

Cardiovascular Systems' (CSII) encouraging REACH PVI study outcome and launch of a physician finder are positives.

Zacks Investment Research - 5 months ago

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?

Business Wire - 6 months ago

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC.

Zacks Investment Research - 6 months ago

Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q4 earnings as patients avoid hospitals.

Zacks Investment Research - 6 months ago

Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q2 earnings as patients avoid hospitals.

Seeking Alpha - 6 months ago

Cardiovascular Systems' (CSII) CEO Scott Ward on Q4 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 2.27% and 10.49%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the ...

Business Wire - 6 months ago

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC.

Benzinga - 6 months ago

Cardiovascular Systems (NASDAQ: CSII) releases its next round of earnings this Tuesday, August 04.

Zacks Investment Research - 7 months ago

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 7 months ago

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS PRESENTS REACH PVI STUDY AT THE NEW CARDIOVASCULAR HORIZONS CONFERENCE

The Motley Fool - 8 months ago

The market is reacting to the company's decision to initiate a public offering of common stock.

Zacks Investment Research - 9 months ago

Cardiovascular Systems (CSII) witnesses a significant decline in procedure volumes in Q3 for patients treated with orbital atherectomy devices.

Seeking Alpha - 9 months ago

Cardiovascular Systems' (CSII) CEO Scott Ward on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 11.11% and -4.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 10 months ago

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 11 months ago

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

Cardiovascular Systems (CSII) continues to register solid top-line growth on strength in the domestic atherectomy businesses.

Zacks Investment Research - 1 year ago

Figuring out bloated toxic stocks on a consistent basis and discarding them at the right time is the key to successful investing.

Other stocks mentioned: HLIT, IAC, MIME, MYGN
Zacks Investment Research - 1 year ago

We are upbeat about Cardiovascular Systems' (CSII) year-over-year uptick in global Coronary and peripheral device revenues during Q2.

Seeking Alpha - 1 year ago

Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -233.33% and 0.65%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead fo...

Zacks Investment Research - 1 year ago

Cardiovascular Systems (CSII) is optimistic about maintaining its growth momentum on several recent developments.

Zacks Investment Research - 1 year ago

This is a major achievement for Cardiovascular Systems (CSII) toward strengthening its portfolio for the treatment of CLI.

Zacks Investment Research - 1 year ago

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

We are upbeat about the year-over-year uptick in both Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.

About CSII

Cardiovascular Systems, a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary o... [Read more...]

Industry
Medical Devices
IPO Date
Feb 26, 2009
CEO
Scott Ward
Employees
779
Stock Exchange
NASDAQ
Ticker Symbol
CSII
Full Company Profile

Financial Performance

In 2020, CSII's revenue was $236.55 million, a decrease of -4.63% compared to the previous year's $248.02 million. Losses were -$27.24 million, 10,580.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for CSII stock is "Buy." The 12-month stock price forecast is 47.00, which is an increase of 13.58% from the latest price.

Price Target
$47.00
(13.58% upside)
Analyst Consensus: Buy